Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 06 May 2014 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) is out with new information about an initiative first announced in 2013 that is meant to convert the labeling of hundreds of older drugs into a newer and consumer-friendly format.
In 2006, FDA passed the Physician Labeling Rule (PLR), a labeling format intended to make it easier for physicians and patients to understand some of the most important benefits and risks of a drug.
For example, labeling highlights under the PLR are limited to half a page, including bulleted boxed warnings, and labels must also contain a "Table of Contents" and identify all major changes made to the label over time.
The label was also reformatted to allow for the most pertinent information to be more prominent, and established 8-point minimum font and other typography requirements to make the type easier to read. Notably, the new labeling also included contact information (phone number and a website address) to facilitate adverse event reporting.
The rule applies to all products approved under a New Drug Application (NDA), Biologics Licensing Application (BLA) or efficacy supplement (ES) approved between 2001 and 30 June 2006, as well as all products thereafter.
However, older drugs did not need to comply with the PLR, but could instead subject themselves to the rule on a voluntary basis, FDA said.
That, however, has resulted in a problem for regulators and patients alike. Many companies have not yet updated their labeling. At present, only about 15% of all drug products on the market conform to the PLR, and FDA said in a statement that it was concerned that its efforts to convert labels had run short of expectations.
"If no further action is taken," FDA said, "the only additional drug products with labeling in the PLR format will be new NDAs, BLAs and ED, which are required to be submitted in that format."
So in February 2013, FDA launched a new initiative known as the Prescription Drug Labeling Improvement and Enhancement Initiative (PDLI-EI), a five-year project to be run by an outside contractor, LexisNexis.
See Regulatory Focus' 11 July 2013 story, "FDA Looks to Update, Improve Labeling of Existing Drug Products."
At its most basic, the PDLI-EI is intended to increase compliance by having the contractor do the work-and assume some of the cost-for the companies, which presumably wouldn't otherwise do so on a voluntary basis.
However, FDA has also said it hopes to use the project as an opportunity to make some improvements to the labeling process, such as by better understanding how labeling information is used by the public.
Now the agency is out with still more information explaining more details about the PLR conversion process. In a 6 May 2014 Federal Register notice, FDA says it expects to first approach companies to become involved in the program, which will then need to submit a proposed revision to the draft labeling.
FDA's language in the Register notice seems to indicate its intent to target holders of new drug applications (NDAs) with one or more generic drugs, as changing the labeling of that single NDA would require all others to change their labels as well.
Though approximately 750 prescription products fall outside of the PLR, FDA estimates that it will be contacting 375 application holders. The agency did not explain why approximately half of all grandfathered products would be ignored.
Submissions will take different amounts of time to complete, depending on the type of product. Innovative products approved under an NDA will take just shy of 200 hours to complete a labeling revision, while generic drug products will take an estimated 27 hours.
Because some products will require new packaging to accommodate longer inserts, some companies will responsible for incurring those costs as well, FDA said.
Federal Register Notice
Tags: PDLI-EI, Physician Labeling Rule, PLR, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.